For Americans who depend on lower-cost prescriptions from Canada and other countries, an October deadline that had been approaching like a wall has suddenly moved. U.S. Customs and Border Protection has postponed compliance with key international-mail requirements until January 20, 2027, providing a 90-day reprieve from procedures that lawmakers and patient advocates feared could make routine prescription shipments far more difficult.
The delay does not settle the larger dispute. The government has not restored the old duty-free exemption for low-value packages, nor has it created a blanket exemption for personal medications. Instead, it has given importers, customs brokers and postal operators more time to prepare while federal agencies determine how prescription shipments will be treated under a much more closely monitored customs system.
The Deadline Moved, but the Policy Did Not Disappear
CBP’s final rule moves the compliance date for specific international-mail entry requirements from October 22, 2026, to January 20, 2027. The agency said importers, customs brokers and logistics companies needed additional time to update internal systems, develop procedures for transmitting the required information and build the technology needed to comply. CBP also acknowledged that enforcing the requirements before those systems were ready could disrupt important international postal shipments headed to Americans. For patients worried that their next refill could be caught in customs, those additional 90 days are significant.
But the postponement is narrower than it may initially appear. CBP has not restored the former de minimis exemption that historically allowed many shipments worth $800 or less to enter with simplified treatment. The agency suspended that exemption for international mail earlier in 2026. During the new grace period, the mail-entry system already established by CBP remains in place. In practical terms, January 20 is now the next major deadline, not the end of the policy itself.
Why a Customs Filing Change Matters to Prescription Drugs
The new system is designed to give the government considerably more information about low-value parcels entering through international mail. CBP created an electronic process called Entry Type 13 for qualifying mail shipments worth $2,500 or less. Filers may need to provide information such as the merchandise description, country of origin, 10-digit tariff classification, value, duty rate, carrier and foreign postal tracking number. The system operates through CBP’s Automated Commercial Environment, bringing parcels that traditionally moved through relatively streamlined postal channels into a more structured customs process.
Prescription medicines create an additional complication because pharmaceuticals fall under Food and Drug Administration jurisdiction. Mail subject to a partner government agency’s requirements is among the categories affected by the tighter procedures. That does not mean the CBP regulation itself declares a nationwide ban on prescriptions arriving from Canada. Instead, the concern is that the combination of electronic entry requirements, customs-broker responsibilities, bonding and FDA admissibility decisions could make many ordinary personal shipments difficult to process. Canadian pharmacy groups have warned that existing delivery arrangements may become unworkable without additional government guidance or an exemption.
Personal Importation Has Always Operated in a Complicated Legal Space
Americans ordering prescriptions abroad are not using an unrestricted legal right to import whatever medicine they choose. Federal law generally prohibits individuals from importing foreign versions of prescription drugs that do not meet FDA requirements, even when a medication contains the same active ingredient as a product sold domestically. The FDA has nevertheless maintained a personal-importation policy under which officials may exercise enforcement discretion in certain circumstances. That discretion has helped create the practical pathway through which some Americans have received medication from foreign pharmacies for years.
FDA guidance says officials may consider allowing a personal shipment when, among other considerations, a drug is intended for a serious condition for which effective domestic treatment may not be available, the product does not pose an unreasonable risk and the consumer confirms that it is for personal use. Quantities are generally expected to be no more than a three-month supply. That distinction matters now. The question is not simply whether customs can electronically process a package; it is also whether FDA will admit the medicine once officials have detailed information about what the parcel contains. More visibility could mean more predictable enforcement, but patients and pharmacies want clear rules before January.
The 2.3 Million Figure Comes From Peer-Reviewed Research
The estimate at the center of lawmakers’ warnings comes from a 2020 study published in JAMA Network Open. Researchers examined National Health Interview Survey data covering 2015 through 2017 and studied 61,238 adults who reported taking prescription medication. About 1.5% said they had purchased prescription medicines from another country during the previous 12 months to save money. When weighted to the national population represented by the survey, that percentage translated to approximately 2.34 million people.
The number should therefore be understood as a research benchmark rather than a precise count of Americans importing medicine in October 2026. The study itself is now several years old, and advocacy organizations have produced higher contemporary estimates. Still, it remains one of the strongest nationally representative measurements available. Researchers also found that foreign purchasing was connected to financial pressure. Uninsured adults, people with lower family incomes and people who had skipped medication or delayed filling prescriptions to save money were more likely to report purchasing medicine outside the United States. That makes the customs debate inseparable from the larger question of drug affordability.
The Price Gap Explains Why Patients Look Across the Border
The appeal of international pharmacies becomes easier to understand when U.S. drug prices are compared with those overseas. Research commissioned by the Department of Health and Human Services found that in 2022, U.S. prices across prescription drugs were about 2.78 times prices in a group of comparable countries. The disparity was particularly large for brand-name medicines, even after researchers attempted to account for rebates and discounts. Generics can produce a different picture, but patients taking expensive branded drugs can encounter dramatic differences between domestic and international prices.
Those pressures remain visible in current polling. A 2026 KFF survey found that 43% of U.S. adults reported taking at least one step during the previous year that meant not using medication as prescribed because of cost. That included people who did not fill prescriptions, substituted over-the-counter products, cut pills or skipped doses. Against that backdrop, purchasing abroad can become less of a shopping decision than an affordability strategy. Advocates have cited the blood thinner Eliquis as one example where a three-month Canadian mail-order supply may cost hundreds of dollars less than certain U.S. retail options.
For Some Patients, the Debate Is About Continuity of Treatment
The consequences become more concrete when a customs procedure reaches the medicine cabinet. Associated Press reporting highlighted Susan Hooper, a 75-year-old Ohio resident who obtains medications from Canada and has serious drug allergies that limit her choices. She told the AP that the cost of one medication, theophylline, had already risen substantially and that another respiratory medication had also become considerably more expensive. Facing uncertainty over the mail rules, she was among patients trying to make sure they had enough medicine to avoid an interruption.
That kind of response helps explain why patient groups reacted so strongly to the October deadline. Prescription therapy for conditions such as cardiovascular disease, respiratory illness, diabetes and other chronic disorders often depends on consistency. Even when another drug technically exists in the United States, changing treatment can require a physician’s involvement, new insurance authorization or substantially higher out-of-pocket spending. The concern is therefore broader than whether a parcel arrives a few days late. For patients who have built their treatment budgets around international purchasing, losing that channel can abruptly transform a manageable monthly expense into a much larger financial obligation.
Pressure on the Administration Has Crossed Party Lines
Opposition to an abrupt change did not come exclusively from one side of Congress. Democratic Representatives Jan Schakowsky of Illinois and Mark Pocan of Wisconsin led a letter joined by 71 House members urging federal agencies to protect access to genuine, non-controlled prescription medicines obtained internationally for personal use. The lawmakers specifically raised the 2.3 million estimate and asked officials to clarify how personal-use medicines would be treated under the new mail system rather than allowing them to be routinely rejected.
Republican concern emerged separately. Florida Representatives Aaron Bean, Gus Bilirakis and C. Scott Franklin also pressed federal officials, arguing that constituents seeking relief from high U.S. drug prices should not be unintentionally harmed. Their geographic argument was straightforward: residents of states bordering Canada may sometimes have the option of traveling to a Canadian pharmacy, while a retiree in Florida generally depends on mail delivery. The CBP postponement followed this growing pressure, although the agency publicly framed its decision around implementation readiness and the risk of postal disruptions rather than attributing it to congressional lobbying.
January 20 Is Now the Date Patients and Pharmacies Are Watching
The next three months will determine whether the delay becomes a transition to workable rules or merely postpones the same dispute. CBP has provided additional preparation time, and its Entry Type 13 test gives the trade community an opportunity to adapt to electronic filing. Federal officials could also issue further guidance explaining how FDA-regulated personal-use prescription shipments will be processed. What has not happened, as of October 22, is a government announcement establishing a broad exemption specifically protecting prescriptions purchased from licensed Canadian and international pharmacies.
That uncertainty is why pharmacy organizations are describing the extension as temporary relief rather than a permanent victory. The Canadian International Pharmacy Association believes most routine personal prescription shipments could become difficult or impossible under the forthcoming arrangements unless policy changes, but that is an industry assessment—not an announcement by CBP that every foreign prescription will be rejected. FDA continues to describe personal importation as a case-by-case matter. For millions of Americans searching outside the country because domestic prices remain unaffordable, the central question is therefore unresolved: when January 20 arrives, will tighter border controls distinguish legitimate personal medication from genuinely dangerous imports without closing an affordability lifeline in the process?
